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Abstract : We aimed to assess the differential diagnostic efficacy of dynamic F-18 fluorodeoxyglucose (FDG) pos-
itron emission tomography / computed tomography (PET / CT) and to evaluate the appropriate scan timings for 
diagnosis of musculoskeletal lesions (MSLs). Dynamic scans (5–15 [phase 1], 15–25 [phase 2], and 25–35 [phase 3] 
min after F-18 FDG injection) and dual-time-point scans (1 and 2 h after injection) were acquired for 23 MSLs [4 
benign MSLs (BMSLs). 10 primary malignant musculoskeletal tumors (PMMSTs), and 9 metastatic musculoskel-
etal tumors (MMSTs)]. We compared the maximum standardized uptake values (SUVmax) and corresponding 
retention indices for dynamic (RI-SUVdyn) and dual-time-point (RI-SUVdual) scans and evaluated diagnostic 
efficacy using receiver operating characteristic (ROC) curve analyses. The SUVmax gradually decreased or was 
almost identical with minimal fluctuation in 3 BMSLs and 1 PMMST. SUVmax increased over time after phase 2 
in 18 malignant MSLs (MMSLs). There were significant differences in SUVmax (for all time phases) and RI-SUV
dual between BMSLs and MMSLs and between PMMSTs and MMSTs. In the ROC analyses, the areas under the 
curve for SUV in phases 2 and 3 were highest for differentiating BMSLs from MMSLs and PMMSTs from MMSTs, 
respectively. Dynamic F-18 FDG PET / CT is valuable for diagnosis of musculoskeletal lesions. J. Med. Invest. 68 : 
96-104, February, 2021
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INTRODUCTION
 
Bone and soft tissue tumors have several physiological, bio-
chemical, and genetic characteristics. In clinical practice, or-
thopedic surgeons and radiologists encounter musculoskeletal 
lesions (MSLs) of unknown origin. It is important to differen-
tiate the benign and malignant lesions to justify performing a 
biopsy and initiating optimal treatment. However, differentiat-
ing between the lesions can be difficult without typical imaging 
findings, leading to a diagnostic dilemma with respect to benign 
MSLs (BMSLs), primary malignant musculoskeletal tumors 
(PMMSTs), and metastatic musculoskeletal tumors (MMSTs). 
In patients with typical imaging findings or with a metastatic 
primary site, MSLs can be diagnosed using conventional mor-
phologic imaging and metabolic imaging modalities, such as 
plain radiography, computed tomography (CT), and magnetic 
resonance imaging (MRI). Functional imaging techniques, 
including Tl-201 scintigraphy, Tc-99m (V) dimercaptosuccinic 
acid (DMSA) scintigraphy, and positron emission tomography 
(PET), are used to obtain complementary information in specific 
clinical situations (1-6). However, the morphological appearance 
and metabolism of these tumors overlap, and a reliable imaging 
method is not available to date.
Recently, several studies have reported absolute PET quantifi-
cation of physiological parameters using tracer kinetic modeling 
(7-12). Dynamic PET imaging is expected to aid in understand-
ing the pathophysiological mechanisms of diseases and extract-
ing physiological or biochemical parameters via tracer kinetics. 
Despite its value, dynamic PET imaging with kinetic model 
analysis is primarily confined to research centers and not used 
in busy clinical settings, mainly because it is technically de-
manding (13). Technical developments in 18F-fluorodeoxyglucose 
(FDG) PET / CT using dynamic scans have enabled the estima-
tion of perfusion-dependent FDG uptake and metabolic activ-
ity in various tumors (14-18). Recent studies have shown that 
dynamic PET / CT in list-mode, without kinetic model analysis, 
can be a simple tool for predicting pathological and clinicopath-
ological tumor characteristics (14, 15, 19, 20). However, to our 
knowledge, no studies have reported the diagnostic performance 
of dynamic 18F-FDG PET / CT in list-mode for differentiation be-
tween BMSLs and malignant musculoskeletal lesions (MMSLs), 
and between PMMSTs and MMSTs.
The present study aimed to assess the efficacy of early dy-
namic PET / CT scanning with list-mode and dual-time-point 
(DTP) PET / CT scanning to differentiate between malignant 
and benign lesions in patients with newly diagnosed MSLs. We 
also compared the diagnostic capacity of dynamic PET / CT and 
DTP PET / CT for MMSLs and identified the most appropriate 
imaging phase for differentiating between the MSLs.
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PATIENTS AND METHODS
All procedures performed in this study that involved human 
participants were in accordance with the ethical standards of 
the institutional research committee and with the 1964 Helsinki 
Declaration and its later amendments or comparable ethical 
standards. This study was approved by the Ethics Committee 
of Tokushima University Hospital (Approval number 2606). 
Informed consent was obtained from all participants included 
in the study. 
Study population
We included patients with MSLs of unknown origin, for whom 
the diagnosis was finally determined by pathological examina-
tions. Additional inclusion criteria were as follows : no therapy 
for MSLs before PET / CT and no history of malignancy within 
the last 3 years.
18F-FDG PET / CT procedures 
Before intravenous injection of 18F-FDG (8.0 × 10-5 Ci / kg of 
body weight), all patients fasted for > 5 h and achieved a blood 
glucose level of < 150 mg / dL. PET / CT was conducted using a 
single PET / CT system (Discovery PET / CT 710 ; GE Health-
care, Chicago, IL, USA) enabled with list-mode data acquisition 
function and four-dimensional data acquisition (i.e., dynamic 
scanning). The protocol included 3 acquisitions : (1) dynamic 
PET acquisition (limited to the single-bed position), (2) low-dose 
CT scan centered on the largest MSL of interest and initiated 5 
min after 18F-FDG injection, and (3) DTP static PET / CT scan 
of the torso (lasting approximately 12–16 min). All participants 
underwent dynamic and DTP PET / CT examinations with their 
upper limbs down.
During the first acquisition, low-dose CT was performed to 
determine PET attenuation correction, anatomical information, 
and image fusion. During the second acquisition, dynamic 18F-
FDG PET / CT was performed as list-mode continuous scanning, 
beginning 5 min after FDG bolus injection and continuing for 
30 min, with every measured value stored as raw data with the 
exact time stamp. The dynamic series were acquired with the 
field of view over the lesions of interest (limited to a single-bed 
position, with longitudinal coverage of 15.042 cm). Patients were 
asked to lie motionless during dynamic scanning. We subse-
quently reconstructed the data as 3 frames at 600-s intervals. 
The list-mode files were reconstructed on the PET / CT scanner 
using three-dimensional, attenuation-weighted, ordered-subset, 
expectation maximization, with 2 iterations and 16 subsets 
(VUE Point FX ; GE Healthcare), a 4-mm post-reconstruc-
tion Gaussian filter, attenuation image segmentation, and a 
192 × 192-pixel matrix. The patient then waited in a waiting 
room before returning to the scanner for the subsequent proce-
dure, conducted 60 min after tracer injection.
The DTP PET / CT scanning region for the 1-h early scan en-
compassed the body from the skull vertex to the knee, and for the 
2-h delayed scan, it encompassed the field of view over the MSL 
of interest. Before conducting DTP PET / CT, a second low-dose 
CT scan was immediately performed for attenuation correction 
over the shooting range. The early and delayed PET scans were 
acquired at 8- and 4-bed positions and for 120 and 180 s, respec-
tively. For each scan, we used the same image reconstruction 
method used for dynamic FDG PET.
PET / CT image analysis
The dynamic and DTP PET / CT images were reviewed by 
2 nuclear medicine physicians (with > 15 years of experience) 
blinded to all clinical, pathological, and other imaging findings. 
In case of disagreement, they reached a consensus via discussion. 
Any obvious foci within the MSL that showed increased FDG 
uptake relative to the surrounding tissue, which could not be 
explained by the physiological uptake of the tracer in these sites, 
were considered positive.
Using the PET / CT images, we carefully placed the volume of 
interest (VOI) on the MSL to exclude FDG accumulation in the 
normal tissue and large vessels, and circular VOIs were drawn 
to encompass each lesion contour on transaxial images. These 
VOIs were placed after consensus was reached between the 2 
nuclear medicine physicians.
For the semiquantitative analysis of FDG uptake, we adopted 
the standardized uptake value (SUV), which was calculated, as 
follows : 
SUV = concentration of radioactivity (Ci / kg) × [lean body 
mass (kg) / injected radioactivity (Ci)]
To minimize partial-volume effects, SUVmax within VOIs 
was used. SUVmax was measured for each dynamic phase 
(SUV1, 5–15 min ; SUV2, 15–25 min ; and SUV3, 25–35 min), 
the 1-h early phase (SUV4), and the 2-h delayed phase (SUV5). 
Furthermore, we calculated the retention index (RI)-SUVmax 
from the SUVmax as follows : 
Retention index of the dynamic phase SUVmax (RI-SUV-
dyn [%]) = (SUV3 – SUV1) × 100 / SUV1
Retention index of DTP SUV (RI-SUVdual [%]) = (SUV5 
[delayed scan] – SUV4 [early scan]) × 100 / SUV4 (early 
scan).
In addition, we calculated the mean SUV (SUVmean) for each 
subject.
The maximal diameter of each tumor lesion was measured on 
axial low-dose CT images.
Statistical analysis
To analyze differences in SUVmax among different phases, 
RI-SUVdyn, and RI-SUVdual, we employed the Mann–Whitney 
U-test for comparisons between BMSLs and MMSLs and the 
Kruskal–Wallis test followed by the Steel–Dwass test for com-
parisons among BMSLs, PMMSTs, and MMSTs.
If the Mann–Whitney U-test and Kruskal–Wallis test fol-
lowed by the Steel–Dwass test revealed a significant difference 
in each index among the groups, we performed additional receiv-
er operating characteristic (ROC) curve analyses for SUVmax 
and RI-SUVmax to evaluate the predictive performance of these 
indices in differentiating between MSL types. Discriminatory 
ability was assessed using the area under the ROC curve (AUC) 
values. We determined the optimal cut-off values that maxi-
mized the sensitivity and specificity for each index and the corre-
sponding sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (NPV), and accuracy. Significant 
differences between 2 AUC values were assessed using Delong’s 
test. All statistical analyses were conducted using EZR version 
1.37 (Saitama Medical Center, Jichi Medical University, Saitama, 
Japan ; available at www.jichi.ac.jp / saitama-sct / SaitamaHP.
files / statmedEN.html), a graphical user interface for R (The 
R Foundation for Statistical Computing, Vienna, Austria) (21). 
Statistical significance was set at p < 0.05.
RESULTS
Patient and tumor characteristics
The patient and tumor characteristics are presented in Table 
1. Between January 2016 and October 2016, 19 patients met the 
inclusion criteria and underwent dynamic and DTP 18F-FDG 
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PET / CT (12 men, 7 women ; age [mean ± SD] 69.21 ± 10.40, 
range 37–81 years). Twenty-three lesions were identified as bone 
and soft tissue lesions on PET / CT evaluations (15 soft tissue, 8 
bone). The MSLs were classified according to the WHO Classifi-
cation of Tumours of Soft Tissue and Bone, Fourth Edition (22), 
by pathologists blinded to the PET results. Histopathologically, 
4 lesions (17%) were classified as BMSLs, 10 (44%) as PMMSTs 
(soft tissue tumors : 7 grade [G] 2 ; bone tumors : 2 G2 and 1 G3), 
and 9 (39%) as MMSTs. Of the 4 bone metastases, 3 were soli-
tary bone tumors.
The tumor diameters ranged from 20 to 245 mm, with most le-
sions having a long-axis diameter of < 60 mm. There was no sig-
nificant between-group difference in the tumor size (p = 0.117).
Visual evaluation
All MMSLs and 2 BMSLs were FDG-positive on all dynamic 
phases and the 1-h early and 2-h delayed phases. In contrast, one 
osteochondroma was FDG-negative on all dynamic phases and 
the 1-h early and 2-h delayed phases, and another osteochon-
droma was negative on the dynamic first and second phases but 
positive on the dynamic third phase and the 1-h early and 2-h 
delayed phases. 
SUVs and RI-SUVmax
SUVmax, RI-SUVmax, and SUVmean values are summa-
rized in Tables 2 and 3. SUV1 was slightly higher than SUV2 for 
2 BMSLs and 5 PMMSTs. For all other lesions, SUV2 was high-
er than SUV1. After the dynamic second phase, SUVmax grad-
ually decreased or was near identical, with little fluctuation, for 
3 BMSLs and 1 PMMST. In contrast, SUVmax increased over 
time after the dynamic second phase for 1 BMSL, 8 PMMSTs, 
and all MMSTs.
SUVmax for each time phase and RI-dual were signifi-
cantly higher for MMSLs than for BMSLs (p = 0.012 for 
SUV1 ; p = 0.00158 for SUV2 ; p = 0.00158 for SUV3 ; p = 0.00581 
for SUV4 ; p = 0.00158 for SUV5 ; p = 0.00858 for RI-dual). All 
SUVmax values were significantly higher for PMMSTs than for 
BMSLs (p = 0.04771 for SUV1 ; p = 0.01621 for SUV2 ; p = 0.0162 
for SUV3 ; p = 0.0195 for SUV4 ; p = 0.0162 for SUV5). All meta-
bolic parameters were significantly higher for MMSTs than for 
BMSLs (p = 0.01355 for SUV1 ; p = 0.00548 for SUV2, SUV3, 
SUV4, and SUV5 ; p = 0.006851 for RI-dyn ; p = 0.0005479 
for RI-dual). SUVmax for each time phase and RI-dyn were 
significantly higher for MMSTs than for PMMSTs (p = 0.0143 for 




conventional imaging Tumor site
Diameter
 (mm)
A. Benign musculoskeletal lesion 
1 / 1 / 80 / male Osteochondroma Osteochondroma Knee 20
2 / 2 / 68 / male Osteochondroma Osteochondroma Knee 40
3 / 3 / 67 / male Hematoma Chronic expanding hematoma Femur 245
4 / 4 / 77 / male Schwannoma Schwannoma Axilla 56
B. Primary malignant musculoskeletal tumor 
5 / 5 / 68 / female Chondroblastic osteosarcoma Chondrosarcoma Ilium 110
6 / 6 / 74 / female Dedifferentiated liposarcoma Liposarcoma Thigh 100
7 / 7 / 59 / male Pleomorphic leiomyosarcoma Soft tissue sarcoma Lower back 79
8 / 7 / 59 / male Pleomorphic leiomyosarcoma Soft tissue sarcoma Lower back 28
9 / 8 / 55 / male Myxofibrosarcoma Soft tissue sarcoma Thigh 57
10 / 9 / 81 / male Pleomorphic leiomyosarcoma Soft tissue sarcoma Back 48
11 / 10 / 65 / female Chondrosarcoma Chondrosarcoma Femur 190
12 / 11 / 37 / female Myxoid liposarcoma Soft tissue sarcoma Thigh 108
13 / 12 / 70 / male Myxofibrosarcoma Soft tissue sarcoma Shoulder 66
14 / 13 / 71 / female Chordoma Chordoma Sacrum 30
C. Metastatic musculoskeletal tumor 
15 / 14 / 79 / male SCC from lung cancer Bone metastasis Ilium (bone) 81
16 / 15 / 67 / female AC from lung cancer Bone metastasis Ilium (bone) 92
17 / 15 / 67 / female AC from lung cancer Metastatic soft tissue tumor Lower back (muscle) 24
18 / 16 / 78 / female AC from gastric cancer Soft tissue sarcoma Thigh (muscle) 79
19 / 17 / 71 / male SCC from hypopharyngeal cancer Metastatic soft tissue tumor Neck (muscle) 21
20 / 17 / 71 / male SCC from hypopharyngeal cancer Metastatic soft tissue tumor Neck (muscle) 28
21 / 17 / 71 / male SCC from hypopharyngeal cancer Metastatic soft tissue tumor Neck (muscle) 23
22 / 18 / 76 / male AC from lung cancer Bone metastasis Dorsal vertebra 28
23 / 19 / 72 / male Clear cell renal cell carcinoma Bone metastasis Dorsal vertebra 27
AC : adenocarcinoma, SCC : squamous cell carcinoma.
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SUV1 ; p = 0.00145 for SUV2 ; p = 0.000605 for SUV3 ; p = 0.00898 
for SUV4 ; p = 0.00898 for SUV5 ; p = 0.000815 for RI-dyn).
Figures 1, 2, and 3 show representative dynamic and DTP 
18F-FDG PET / CT images of MMSTs, PMMSTs, and BMSLs. 
Figure 4 shows the change in median SUVmax values for each 
time phase per study group.
 
ROC curves and cut-off values for SUVmax and RI-SUVmax
Tables 4 and 5 show the threshold (i.e., cut-off) values for each 
parameter and the resulting sensitivity, specificity, PPV, NPV, 
and accuracy for discriminating between MMSLs and BMSLs 
and between MMSTs and PMMSTs.
For differentiating MMSLs from BMSLs, the cut-off values 
yielded the highest sensitivity of 94.7% and highest specificity of 
100.0%, with PPV, NPV, and accuracy values of 94.7%, 100.0%, 
and 95.7%, respectively, for SUVmax analyses in the dynamic 
second phase. Compared with the AUC derived in all other 
ROC analyses, that for SUV2 was the largest at 0.987 ; however, 
Delong’s test did not reveal any significant differences among 
the AUC values for all parameters (p > 0.05 for all).
For differentiating between the MMSTs and PMMSTs, the 
cut-off values yielded the highest sensitivity of 100.0% and high-
est specificity of 90.0%, with PPV, NPV, and accuracy values of 
90.0%, 100.0%, and 94.0%, respectively, for the SUVmax analy-
ses in the dynamic third phase and RI-SUVdyn. Compared with 
the AUC derived in all other ROC analyses, that for SUV3 was 
the largest at 0.967 ; however, Delong’s test did not reveal any 
significant differences among the AUC values for all parameters 
(p > 0.05 for all).
 
Table 2.　SUVmax and RI-SUVmax values at each time-point in each group
BMSL MMSL PMMST MMST
SUV1 2.53 ± 0.75 4.48 ± 0.35 4.53 ± 0.26 5.72 ± 0.56
(1.45–4.57) (2.57–8.83) (2.57–5.21) (3.69–8.83)
SUV2 2.59 ± 0.41 5.29 ± 0.51 4.19 ± 0.71 6.58 ± 0.34
(1.92–3.65) (2.49–10.65) (2.49–6.00) (4.78–10.65)
SUV3 2.57 ± 0.37 6.29 ± 0.64 4.39 ± 0.45 7.58 ± 0.79
(1.46–3.01) (2.50–12.21) (2.50–7.08) (6.29–12.21)
SUV4 2.56 ± 0.97 9.66 ± 0.20 6.23 ± 1.01 10.77 ± 1.15
(1.86–2.73) (2.53–17.23) (2.53–12.03) (8.57–17.23)
SUV5 2.41 ± 0.23 11.37 ± 1.20 6.94 ± 1.33 13.96 ± 1.38
(1.53–2.80) (1.77–20.75) (1.77–14.16) (9.18–20.75)
RI-SUVdyn -5.65% ± 14.08% 32.52% ± 6.16% 8.68% ± 6.91% 46.08% ± 3.94%
(-47.48–32.52) (-38.93–71.27) (-38.93–45.68) (32.52–71.27)
RI-SUVdual -0.21% ± 3.75% 17.71% ± 4.67% 19.02% ± 6.63% 8.47% ± 6.82%
(-17.74–3.70) (-30.04–65.85) (-30.04–48.15) (4.65–65.85)
SUV, standardized uptake value ; RI-SUV, retention index of maximum standardized uptake value ; BMSL, benign 
musculoskeletal lesion ; MMSL, malignant musculoskeletal lesion ; PMMST, primary malignant musculoskeletal tu-
mor ; MMST, metastatic musculoskeletal tumor ; dyn, dynamic ; dual, dual-time-point
Data are presented as median ± standard error of the mean. Data in parentheses represent the ranges. 
Table 3.　SUVmean at each time-point in each group
BMSL MMSL PMMST MMST
SUV1 1.76 ± 0.58 3.83 ± 0.26 3.61 ± 0.26 4.27 ± 0.41
(1.11–3.59) (2.09–6.20) (2.09–4.28) (2.40–6.20)
SUV2 2.11 ± 0.37 3.67 ± 0.36 3.19 ± 0.32 3.98 ± 0.59
(1.34–3.09) (1.89–7.56) (1.89–5.42) (3.22–7.56)
SUV3 2.10 ± 0.32 4.25 ± 0.39 3.08 ± 0.35 5.25  ± 0.53
(1.27–2.67) (2.10–8.33) (2.10–5.84) (4.01–8.33)
SUV4 2.05 ± 0.23 5.10 ± 0.55 4.0 ± 0.62 6.67 ± 0.65
(1.23–2.24) (2.13–10.18) (2.13–8.81) (4.86–10.18)
SUV5 1.54 ± 0.16 5.66 ± 0.70 4.10 ± 0.71 7.57 ± 0.92
(1.06–1.78) (1.43–14.38) (1.43–9.81) (5.62–14.38)
SUV, standardized uptake value ; BMSL, benign musculoskeletal lesion ; MMSL, malignant musculoskeletal 
lesion ; PMMST, primary malignant musculoskeletal tumor ; MMST, metastatic musculoskeletal tumor.
Data are presented as median ± standard error of the mean. Data in parentheses represent ranges.
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Fig 1.　A 78-year-old woman with metastatic soft tissue tumor from gastric cancer in the left thigh
Positron emission tomography/computed tomography (PET / CT) (A-E) images are shown. On the dynamic phases (A-C), 
fluorodeoxyglucose (FDG) accumulation in the soft tissue tumor is inhomogeneous and focal intense accumulation is identifiable in 
the posterior part from the dynamic first phase (maximum standardized uptake value [SUVmax] : dynamic first phase, 7.41 ; dynamic 
second phase, 9.65 ; dynamic third phase, 11.14). The accumulation gradually becomes intense in most parts of the tumor during the 
dynamic phases (A-C). The 1-h early (D) and 2-h delayed (E) phases show homogeneous and intense accumulation in the soft tissue 
tumor (SUVmax: 1-h early phase, 15.04 ; 2-h delayed phase, 19.52). The time-SUVmax curve (F) shows a high level for the SUVmax for 
the dynamic first phase (SUV1), with a continuous increase during the dynamic (SUV1-3), 1-h early (SUV4), and 2-h delayed (SUV5) 
phases. The physiological FDG uptake of the bone and soft tissue in the early dynamic phase is faint, while the FDG accumulation in the 
tumor is clearly depicted.
Fig 2.　A 74-year-old-woman with differentiated liposarcoma (grade 2) in the right thigh
Positron emission tomography/computed tomography (PET / CT) images are shown for the dynamic (A-C), 1-h early (D), and 2-h delayed 
(E) phases. On the dynamic first phase (A), fluorodeoxyglucose (FDG) accumulation in the soft tissue tumor is inhomogeneous (maximum 
standardized uptake value [SUVmax], 5.21). After the dynamic second phase (B-E), the accumulation gradually becomes fainter and 
more homogeneous and the focal intense accumulation becomes clearer in the left portion of the tumor, compared with accumulation in 
the dynamic first phase (SUVmax : dynamic second phase, 5.63 : dynamic third phase, 6.02 : 1-h early phase, 10.41 : 2-h delayed phase, 
13.35). The time-SUVmax curve (F) shows a gradual increase during the dynamic phases (SUV1-3) and a high level for the SUVmax 
during the 1-h early (SUV4) and 2-h delayed (SUV5) phases, with continuous increase.
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Fig 3.　A 67-year-old-man with chronic expanding hematoma in the left femur
Positron emission tomography/computed tomography (PET / CT) images are shown for the dynamic (A-C), 1-h early (D), and 2-h delayed 
(E) phases. On the dynamic first phase (A), fluorodeoxyglucose (FDG) accumulation in the peripheral region of the bone tumor is focal 
and faint (maximum standardized uptake value [SUVmax], 4.57). After the dynamic second phase (B-E), FDG accumulation gradually 
becomes fainter (SUVmax : dynamic second phase, 3.65 : dynamic third phase, 2.97 : 1-h early phase, 2.73 : 2-h delayed phase, 2.40). The 
time-SUVmax curve (F) shows a low level for SUVmax at the dynamic first phase (SUV1), with a gradual decrease during the dynamic 
(SUV1-3), 1-h early (SUV4), and 2-h delayed (SUV5) phases.
Fig 4.　The change in median SUVmax values for each time phase in benign and malignant musculoskeletal lesions.
Table 4.　Performance of various parameters in discriminating between MMSLs and BMSLs in semiquantitative analyses
SUV1 SUV2 SUV3 SUV4 SUV5 RI-SUVdual
Threshold value 3.49 3.38 3.55 5.16 4.00 4.26
Sensitivity (%) 94.7 94.7 89.5 89.5 94.7 89.5
Specificity (%) 75.0 100.0 100.0 100.0 100.0 100.0
PPV (%) 94.7 94.7 100.0 100.0 100.0 100.0
NPV (%) 75.0 100.0 66.7 66.7 80.0 66.7
Accuracy (%) 91.3 95.7 91.3 91.3 95.7 91.3
AUC 0.895 0.987 0.974 0.980 0.961 0.908
SUV, standardized uptake value ; RI-SUV, retention index of maximum standardized uptake value ; dual, dual-time-point 
scans ; PPV, positive predictive value ; NPV, negative predictive value ; AUC, area under the curve ; MMSLs, malignant muscu-
loskeletal lesions ; BMSLs, benign musculoskeletal lesions.
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DISCUSSION
To date, no studies have evaluated the diagnostic capabilities 
of dynamic 18F-FDG PET / CT in differentiating between ma-
lignant and benign primary unknown MSLs. In this study, we 
assessed the changes in 18F-FDG uptake in MSLs on dynamic 
PET / CT scans to compare their diagnostic capacity with that of 
DTP PET / CT scans. We also attempted to determine the phase 
that can provide the most accurate diagnostic information for 
MSLs. 
In clinical functional imaging, the most popular method to 
diagnose malignancies is static PET imaging. The relatively 
weaker physiological accumulation of FDG in the bone and 
soft tissues, makes assessing the accumulation of FDG in mus-
culoskeletal lesions easier compared to that in other organs. 
PMMSTs are typically 18F-FDG-avid, while BMSLs show a faint 
18F-FDG uptake on static PET images. Reportedly, when using 
semiquantitative SUV-based methods in MSL cases, the utility 
of DTP scanning to evaluate FDG accumulation changes over 
time. In a prospective study of 67 patients with bone lesions (23), 
there were significant differences in SUVmax in the 1-h early 
phase and RI, with a sensitivity, a specificity, and an accuracy 
of 90.6%–96.0%, 44.0%–76.0%, and 72.4%–83.7%, respectively. 
The AUC values for RI were significantly greater than those 
for SUVmax in the 1-h early phase. In another study of 56 soft 
tissue tumors (24), there were significant differences in SUVmax 
between benign and malignant tumors on the 1-h early and 2-h 
delayed phases. However, low-grade malignant tumors show 
mild 18F-FDG uptake and granulomas and active inflammation 
show false-positive findings on DTP scans (24, 25). Therefore, 
MSLs may show variable 18F-FDG uptake, and conventional 18F-
FDG PET may have a limited role in the diagnosis of low-grade 
sarcomas and benign lesions (8, 26).
The present study showed transitional patterns of continually 
increasing 18F-FDG uptake in most MMSLs and revealed that 
FDG avidity is stronger in MMSLs than in BMSLs from the 
early dynamic phase to the delayed phase. Especially, different 
from those for the BMSLs and PMMSTs, the SUVmax value in 
the dynamic second phase was higher than that in the dynamic 
first phase for all MMSTs. We found significant differences in 
the SUVmax for each time phase and RI-dyn between MMSTs 
and PMMSTs. In the included patients population, the median 
RI values for BMSLs were lower in the dynamic scans than in 
the DTP scans. According to a previous report, the SUVmax for 
16 of 17 chronic bacterial osteomyelitis cases was stable or de-
creased between 30 and 90 min after injection, and the median 
SUVmax for 4 malignant lesions was 3.19 (range 2.31−4.70) at 
30 min and 4.1 (range 3.52−5.32) at 90 min (26). Another report 
revealed a significant difference in the mean RI values between 
benign and malignant bone tumors on 2-h DTP scans (23). In 
the first few minutes after FDG injection, the FDG uptake is pri-
marily determined by blood perfusion and vascular permeability 
in the specific tissue. In the subsequent metabolic phase, FDG is 
gradually accumulated in metabolically active cells (9). Our find-
ings suggest that most MMSLs show progressively increasing 
FDG avidity from the early dynamic phase to the 2-h delayed 
phase and that FDG avidity is stronger at 5−35 min than at 
60−120 min after injection. The amount of FDG metabolized in 
most MMSTs is greater than that metabolized in BMSLs and 
PMMSTs from the early dynamic phase, and it may be a key 
finding for differentiating between MMSTs and BMSLs and 
PMMSTs. FDG accumulation in BMSLs, except for granulomas, 
and active inflammation may continuously decrease or remain 
stable from the early dynamic phase.
Regarding differentiation between MMSLs and BMSLs, this 
study demonstrated a high diagnostic capacity for SUVmax cut-
off value of 3.38, based on the ROC curve analysis of the dynamic 
second phase (AUC 0.987). In addition, although Delong’s test 
did not reveal any significant differences among the AUC values 
for all parameters, ROC curve analysis for the dynamic third 
phase showed the highest diagnostic ability at the SUVmax cut-
off value of 6.29 for differentiating MMSTs from PMMSTs (AUC 
0.967). In dynamic PET studies without list-mode, the evaluation 
of full FDG kinetics and application of discriminant analysis are 
required and can be prospectively used to classify bone lesions as 
malignant or benign. A study (8) showed that this method had 
a sensitivity, a specificity, and an accuracy of 75.9%, 97.2%, and 
87.7%, respectively. On 18F-FDG PET studies in patients with 
MSLs, tumor heterogeneity, the number of granulomas, active 
inflammation, and low-grade sarcoma may affect the outcome 
of dynamic PET / CT imaging. Hence, our results suggest that 
the analysis of FDG accumulation in the early dynamic phases 
is a valuable predictor for discriminating MSLs and show that 
the diagnostic capacity of SUVmax on the dynamic second and 
third phases is equivalent or superior to that on the 1-h early and 
2-h delayed PET / CT scans in our study population. Therefore, 
a diagnostic accuracy equal to that obtained using the 60-min 
and 120-min protocols used in clinical contexts can be obtained 
with a single measurement requiring 15–25 min. The diagnostic 
capacity of this approach alone may not be sufficient to differ-
entiate between MSLs or be used as the basis for changing the 
current standard diagnostic flow, which is dependent on biopsy. 
However, the early dynamic PET / CT scans in list-mode may aid 
the prediction of histopathology in cases where it is impossible to 
Table 5.　Performance of various parameters in discriminating between MMSTs and PMMSTs in semiquantitative analyses
SUV1 SUV2 SUV3 SUV4 SUV5 RI-SUVdyn
Threshold value 5.06 6.19 6.29 8.57 9.18 32.52
Sensitivity (%) 77.8 77.8 100.0 100.0 100.0 100.0
Specificity (%) 90.0 100.0 90.0 70.0 70.0 90.0
PPV (%) 87.5 100.0 90.0 75.0 75.0 90.0
NPV (%) 81.8 83.3 100.0 100.0 100.0 100.0
Accuracy (%) 84.2 89.5 94.7 84.2 84.2 94.7
AUC 0.833 0.933 0.967 0.856 0.856 0.956
RI-SUV, retention index of maximum standardized uptake value ; Dyn, dynamic scans ; PPV, positive predictive value ; NPV, 
negative predictive value ; AUC, area under the curve ; SUV, standardized uptake value ; PMMSTs, primary malignant mus-
culoskeletal tumors ; MMSTs, metastatic musculoskeletal tumors.
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perform percutaneous biopsy and where there are multiple sites 
with various suspected morphological subtypes.
This study was limited by the small sample size and lack of 
granuloma and active inflammation cases, which show FDG 
avidity (false-positive) on routine FDG PET scans. Moreover, we 
did not assess the pathological background responsible for differ-
ences among MSLs in FDG uptake, which involves the expres-
sion of glucose transporters in the tumors, and did not perform 
kinetic modeling in FDG PET. A multi-institutional trial using a 
larger patient population that includes all histological subtypes, 
combined with a kinetic study and immunohistochemical analy-
sis, may provide a clearer picture and more comprehensively re-
veal the diagnostic capacity of dynamic 18F-FDG PET / CT scans 
for MSLs. Despite its limitations, this study demonstrated the 
high diagnostic ability of this approach for MMSLs and MMSTs 
with an optimal cut-off SUVmax. In addition, our dynamic 18F-
FDG PET / CT analysis can be routinely performed in clinical 
practice without additional invasive methods, such as continuous 
phlebotomy for arterial input function.
In conclusion, this study reported a transitional increase in 
the 18F-FDG uptake in MMSLs and that FDG avidity was stron-
ger in MMSLs than in BMSLs from the early dynamic phase 
to the 2-h delayed phase. In the included patients population, 
dynamic 18F-FDG PET / CT, particularly when combined with 
semiquantitative analyses for SUV2 and SUV3, showed high 
diagnostic accuracy in differentiating between MSLs. Additional 
studies with larger cohorts are needed to identify the modality−
dynamic PET / CT or DTP scanning−that performs better in 
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